Within the past 3 years, University Retina has built their program to be one of the largest clinical trial programs in the Midwest for retinal and macular conditions.
We have a full-time team dedicated to our Clinical Trials program and are able to offer our patients the latest innovative drug and medical device therapeutics for treating retinal and macular diseases. If you are interested in learning more or participating in a clinical trial for macular or retinal disease, please contact us using the button below.
Director of Clinical Research Veeral Sheth, MD, FACS
What are Clinical Trials?
Clinical trials are research studies that look into advanced and cutting edge treatments for diseases of the macula or retina that are not offered to the general public. Clinical trials are generally sponsored by governmental agencies such as the National Institute of Health (NIH), pharmaceutical companies, or non-profit institutions. These therapies may not be currently approved by the Food and Drug Administration (FDA), and data from these studies is often used to help obtain FDA approval.
Participation in clinical trials is never mandatory; our patients only participate if they choose to do so. University Retina, its staff, physicians, and patients participate in clinical trials in order to be able to offer our patients with the latest therapies available for macular diseases and retinal diseases.
How can I participate in a Clinical Trial at University Retina?
Patients that are interested in clinical trials should contact us to schedule an appointment at (708) 687-2222. Please set up an appointment to be evaluated if you are interested in participating, and we will determine whether you qualify for one of our active and enrolling clinical trials.
Please note that not everyone who wishes to participate will be eligible to participate in the trial, as the criteria for inclusion in the trial are often very strict. Regardless of whether you are able to participate or not, the University Retina team is committed to helping all of our patients with their retinal care.
Current Studies
Altitude (RGX-314-2202): Phase II, Randomized, Controlled, Dose-escalation Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via a Single Suprachoroidal Space (SCS) Injection in Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME). Sponsor: AbbVie Inc.
Atmosphere (RGX-314-2104): A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE) Sponsor: AbbVie Inc.
Elevatum (ML3435): PHASE IV, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE FARICIMAB (RO6867461) TREATMENT RESPONSE IN TREATMENT-NAÏVE, UNDERREPRESENTED PATIENTS WITH DIABETIC MACULAR EDEMA. Sponsor: Genentech, Inc.
INSITE (2022-01): Treat & Extend versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Randomized, Controlled Trial. Sponsor: McMaster University
AVD-104-C01: A Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Treatment Effect of Intravitreal AVD-104 in Participants with Geographic Atrophy Secondary to Age related Macular Degeneration. Sponsor: Aviceda Therapeutics, Inc.
SOL (OTX-TKI-2023-AMD-301): Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration. Sponsor: Ocular Therapeutix, Inc.
RGX-314-5201: A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of Suprachoroidal Administration of RGX-314 for Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema. Sponsor: REGENXBIO Inc.
RGX-314-5101: A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy. Sponsor: AbbVie Inc
ReNEW (SPIAM-301): Phase III, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects who have Dry Age-Related Macular Degeneration (Dry AMD). Sponsor: Stealth BioTherapeutics Inc.
SOL-R (OTX-TKI-2023-AMD-303): Phase III, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration. Sponsor: Ocular Therapeutix, Inc.
Sienna (R3918-AMD-2326): A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (AMD). Sponsor: Regeneron Pharmaceuticals, Inc.
NOVA STAGE 2 (RTE88-E0001): A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration. Sponsor: Alcon Research
4FRONT (4D-150-C003): A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration. Sponsor: 4D Molecular Therapeutics, Inc.
ARTEMIS (ADVM-022-12): A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration. Sponsor: Adverum Biotechnologies, Inc.
JADE (OLN324-CP-010): A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Two Different Formulations of Intravitreal OLN324 in Adult Participants with Either Neovascular (Wet) Age-related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME). Sponsor: Ollin Biosciences, Inc.
THAMES PART 5 (GR43828): A Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of RO7446603 administered alone or in combination with aflibercept or faricimab in patients with diabetic macular edema. Sponsor: Genentech, Inc
ASTELLAS (3021-MA-3543): A non-interventional, observational study to evaluate treatment patterns and safety of avacincapted pegol (ACP/Izervay) in routine clinical practice in patients with geographic atrophy secondary to age-related macular degeneration. Sponsor: Astellas Pharma Global Development, Inc.
Luna (ADVM-022-11): A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). Sponsor: Adverum Biotechnologies, Inc.
Atmosphere (RGX-314-2104): A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD. Sponsor: AbbVie Inc
Belvedere (ML43000): A PHASE IV, MULTICENTER, OPEN-LABEL STUDY TO ASSESS CORNEAL ENDOTHELIAL CELLS IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB (PDS). Sponsor: F. Hoffmann-La Roche Ltd.
Oracle (GT-Oracle): A long-term follow-up study to evaluate the safety of GT005 in participants with geographic atrophy secondary to age-related macular degeneration treated in a Gyroscope- sponsored antecedent study. Sponsor: Novartis
Honu (GE43220): A MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF THE PROGRESSION OF INTERMEDIATE AGE-RELATED MACULAR DEGENERATION. Sponsor: Genentech, Inc.
Brunello (EYE-RES-102): A RANDOMIZED, DOUBLE-MASKED, MULTI-CENTER, 3-ARM PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVITREAL EYE103 COMPARED WITH INTRAVITREAL RANIBIZUMAB (0.5 MG) IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA. Sponsor: Eyebiotech Ltd.
Elara (VGFTe-HD-OD-2444): A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (nAMD) OR DIABETIC MACULAR EDEMA (DME). Sponsor: Regeneron Pharmaceuticals, Inc.
Voyager (MR41927): REAL-WORLD, LONG-TERM DATA COLLECTION TO GAIN CLINICAL INSIGHTS INTO ROCHE OPHTHALMOLOGY PRODUCTS. Sponsor: F. Hoffmann-La Roche Ltd.
Vanotech (VAN-2201): A Phase I, Open-label, Multicenter, Dose- Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration. Sponsor: Chengdu Origen Biotechnology Co., Ltd., a subsidiary of Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Astellas (7317-CL-0003): A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration. Sponsor: Astellas Institute for Regenerative Medicine
Abbvie (RGX-314-5101): A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy. Sponsor: AbbVie Inc
Burgundy (BP41670): A THREE-PART, PHASE I/II STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF ZIFIBANCIMIG FOLLOWING INTRAVITREAL ADMINISTRATION OF MULTIPLE ASCENDING DOSES AND CONTINUOUS DELIVERY FROM THE PORT DELIVERY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Sponsor: F. Hoffmann-La Roche Ltd
Diamond (DX219): A Phase 2/3 Double-masked, Randomized, 2 stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema. Sponsor: Oculis Operations
Lugano (EYP-1901-301): A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD. Sponsor: EyePoint Pharmaceuticals, Inc.
Sanofi (DFI17940): A Phase 1/2 dose escalation and dose expansion study to evaluate the safety, tolerability, and efficacy of one-time intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration. Sponsor: Sanofi-Aventis Recherche & Développement
Barolo (EYE-RES-103): A Randomized, Double-masked, Multi-center, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema. Sponsor: Eyebiotech Ltd.
Super Tuscan (EYE-RES-104): A Phase 2 randomized dose-masked study of intravitreal (IVT) EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). Sponsor: Eyebiotech Ltd.
DFI18231 (DFI18231): A Phase 1/2, study to evaluate the safety, tolerability, and efficacy of one-time intravitreal dose of SAR446597 in participants with geographic atrophy secondary to age-related macular degeneration. Sponsor: Sanofi US Services, Inc.
RPT Patch (RPT-14-02): A Phase IIb, Randomized, Assessor-Masked, Multicenter Clinical Trial to Assess the Safety and Efficacy of Subretinal Implantation of the CPCB-RPE1 implant in Subjects with Advanced, Dry Age-Related Macular Degeneration (Geographic Atrophy). Sponsor: Regenerative Patch Technologies LLC
VAN-2401 (VAN-2401): A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration. Sponsor: Chengdu Origen Biotechnology Co., Ltd., a subsidiary of Chengdu Kanghong Pharmaceutical Group Co., Ltd.
"Dr. Rama Jager and his team are world class. You won't find another physician with this level of skill and compassion.""
- Bryan
"Dr. Jager is the most compassionate and capable doctor I've had the pleasure of knowing. My 66 y/o father had floaters in his eye and got an appointment and (painless) laser procedure within the SAME DAY. Dr. Jager took the time to explain what was wrong and gave a clear solution to my dad's problem. The floaters are gone and, more importantly, our family has been given a peace of mind!""
- Ambika
"Dr. Jager and Byun were awesome! They were very professional and actually cared about my health and vision. The Oak Forest location was by far, fairly priced compared to other local retina specialists. The staff were friendly and the open availability for appointments are immediate. I definitely recommend University Retina. You wont regret it!""
- Tabitha
"I had an eye emergency after cataract surgery that needed to be looked at immediately. Dr. George saw me in the Downers Grove office as soon as I could get there. He gave me the treatment I needed for surgery 5 days later. He and his team are professional experts who treat the patient with kindness and respect. I highly recommend him and his team.""
